Spotlight on SERDs in Breast Cancer

CE / CME

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: July 22, 2024

Expiration: July 21, 2025

Aditya Bardia
Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani
Virginia Kaklamani, MD, DSc
Sarah L. Sammons
Sarah L. Sammons, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For patients with breast cancer with disease progression on CDK4/6i + ET, which mutation would make them candidates for an approved oral selective estrogen receptor degrader?